PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2001Annals of Medicine322 citations

Introducing economic and quality of life measurements into clinical studies

View Full Paper
MDMichael Drummond

Key Points

Key points are not available for this paper at this time.

Abstract

Although the collection of cost and quality of life data alongside clinical studies generates detailed patient level data in a timely fashion, it also raises practical and methodological challenges. These include the fact that the settings and patients enrolled in trials may not be typical of those found in regular clinical practice, that costs and quality of life may be influenced by the trial protocol, that the clinical alternatives compared in trials may not be the most relevant for cost-effectiveness assessments, that the length of follow-up may be too short to observe changes in cost and quality of life, and that adding these data will increase the overall measurement burden in the trial. This paper discusses these challenges and the ways in which they might be overcome, focussing particularly on preference-based measures of quality of life. In particular, recommendations are given for choosing the range of quality of life instruments, sample size calculations for quality of life measurement and the measurement of quality of life in multinational studies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Michael Drummond (2001) studied this question.

synapsesocial.com/papers/6a1a330ab40ad155b43ab810https://doi.org/10.3109/07853890109002088
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project1998 · 2,652 citations
  2. 2The Effects of Antihypertensive Therapy on the Quality of Life1986 · 1,347 citations
  3. 3Should Clinical Trials With Concurrent Economic Analyses Be Blinded?1997 · 26 citations
  4. 4PHT7: THE FRENCH HEALTH UTILITIES INDEX MARK 32000 · 3 citations
  5. 5Explanatory and Pragmatic Attitudes in Therapeutical Trials2009 · 1,262 citations